Chemotherapy in Pediatric-Type Soft-Tissue Sarcomas

K. M. Ingley, S. Cohen-Gogo, A. A. Gupta


Soft-tissue sarcoma (STS) is rare and represents approximately 7% of cancers in children and in adolescents less than 20 years of age. Rhabdomyosarcoma (RMS) is most prevalent in children less than 10 years of age and peaks again during adolescence (16–19 years of age). Multi-agent chemotherapy constitutes the mainstay of treatment for RMS. In other non-rhabdomyosarcoma soft-tissue tumours, such as synovial sarcoma, evidence for routine use of chemo-therapy is less robust, and alternative treatment options, including targeted agents and immunotherapy, are being explored. In this review, we focus on chemotherapy for pediatric-type RMS and discuss the advances and challenges in systemic treatment for select non-rhabdomyosarcoma soft-tissue tumours in children and adolescents. We  support an increasingly cooperative approach for treating pediatric and adult STS.


Chemotherapy; pediatrics; adolescents and young adults; AYAs; rhabdomyosarcoma; non- rhabdomyosarcoma; soft-tissue sarcoma

Full Text:



Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)